|Articles|March 1, 2002

Neurotech wins license to develop Amgen's CNTF

Paris - Neurotech S.A. will exclusively develop and market Amgen Inc.'s ciliary neurotrophic factor (CNTF), a protein that has protective effects in animals with retinitis pigmentosa.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Latest CME